In this edition experts, including Professor Smolen and Professor McInnes, present the latest data for the recently approved JAK inhibitor, upadacitinib. The presentations include: data from the SELECT trials, safety analyses, switching from TNF inhibitors, and the mode of action of upadacitinib.
